My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crucigrama Sopa de Letras Hoja de Trabajo
Calificar este Puzzle:
Log in or sign up to rate this puzzle.

Heart Failure

Horizontales
Drug used in heart failure that should not be initiated in a patient with an eGFR <20 mL/min/1.73m2
A clinical syndrome that is caused by a structural or functional cardiac disorder that impairs the ability of cardiac ventricles to fill with or eject appropriate blood volume to maintain oxygenation
Type of heart failure that is often caused by coronary artery disease
Soluble guanylate cyclase inhibitor used in patients with NYHA class II through IV HF and LVEF <45% and with a recent hospitalization for HF
LVEF previously ≤40% and a follow-up measurement of LVEF >40%
NYHA class in which ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain
Drug used in heart failure that can cause a transient increase in serum creatinine following initiation of therapy
Drug used in heart failure that is contraindicated in Wolff Parkinson White syndrome
Drug that reduces morbidity and mortality in African American patients when added to optimal therapy
Gold standard for the diagnosis of heart failure
Symptom of heart failure defined as shortness of breath when lying flat
Reason for the 36-hour washout period between an ACEi and Entresto
Mortality rates for heart failure are (increasing/decreasing)
Metoprolol formulation approved for use in heart failure
Stage of heart failure with current or previous symptoms
Verticales
Drug class that causes cardiomyopathy (and heart failure) when given in high cumulative doses
Beta blocker that should be taken with food
Most common cause of heart failure with preserved ejection fraction
Drug that decreases morbidity when added to a maximally tolerated beta blocker or when beta blockers are contraindicated
Drug class used for symptom control with no known morbidity or mortality benefit
Preferred RAAS inhibitor in heart failure
MRA that has mortality benefit in patients with a myocardial infarction and LVEF <40%
Drug class with mortality benefit in HFpEF
Gender that is at an increased risk for HFpEF
Trial that evaluated sacubitril-valsartan in ADHF
Loop diuretic with 50% bioavailability
Trial that evaluated metoprolol tartrate vs. carvedilol
Drug class that can worsen heart failure by causing sodium and water retention